Cuprina Holdings (Cayman) Limited is a biomedical and biotechnology company, which is engaged in the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. Its segments include Maggot Debridement Therapy Product (MDT) and Cosmeceutical Product. It manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as MDT, which is an effective alternative to surgical debridement. It has two lines of chronic wound care products in its pipeline, such as Collagen dressings, including sponges, particles and hydrogels utilizing bullfrog collagen derived from the valorization of abattoir waste streams of American bullfrogs (Lithobates catesbeianus) and products utilizing medical leeches for wound treatment.
公司代码CUPR
公司名称Cuprina Holdings (Cayman) Ltd
上市日期Apr 10, 2025
CEOMr. Yong Qi (David) Quek
员工数量14
证券类型Ordinary Share
年结日Apr 10
公司地址Block 1090
城市
上市交易所NASDAQ Capital Market Consolidated
国家Singapore
邮编169201
电话6585127275
网址https://cuprina.com/
公司代码CUPR
上市日期Apr 10, 2025
CEOMr. Yong Qi (David) Quek